21 Jul Harm profile of JAK inhibitors in inflammatory rheumatic conditions
This report reviews open-label randomized and non-randomized experimental studies as well as observational studies of harm associated with the Janus kinase inhibitors (JAKi) tofacitinib and upadacitinib for the rheumatic conditions psoriatic arthritis, ankylosing spondylitis and...